Loading
Every dated change on the records linked to Metastatic and recurrent anal squamous cell carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Response rate 57 percent with cisplatin-fluorouracil against 59 percent with carboplatin-paclitaxel; serious adverse events 62 against 36 percent; median overall survival 12.
A milestone in how this cancer is treated.